Home / Business / Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

collected by :John Locas

follow the latest news about business from different sites most famous technicals /Chris Lau by 2017-01-11 at 1:1

as declared in

Hold Valeant Pharmaceuticals – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Hold Valeant Pharmaceuticals - Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Value investors face paper losses when picking a bottom for a stock.The more the stock falls, the more discounted the stock looks from its intrinsic value.Valeant Pharmaceuticals (NYSE:VRX) faced so many headwinds in 2016 that its only accomplishment on the market was not closing at a yearly low.
.

read more from here

Valeant Pharmaceuticals – 3 Paths To A Multi-Bagger – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Valeant Pharmaceuticals - 3 Paths To A Multi-Bagger - Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Debt levels are high, but could be managed and debt refinancing is an option as well.Valeant (NYSE:VRX) is a hated stock with a very cheap valuation (due to bankruptcy fears, perhaps a bit overblown as you will see below).I believe Valeant is currently near the point of maximum pessimism, which provides investors with the maximum return potential.
.

read more from here

Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Stock Alert – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Valeant Pharmaceuticals International, Inc.’s (VRX)’s Stock Price Trading Update:Valeant Pharmaceuticals International, Inc.’s (VRX) ended its day with a gain of 0.39% and finalized at the price of $15.35.During its last trading session, Stock traded with the total exchanged volume of 9.52 million shares.The average volume stands around 18.33 million shares.
.

read more from here

Valeant Is A Strong Acquisition Target – Valeant Pharmaceuticals International, Inc. (NYSE:VRX)

Valeant Is A Strong Acquisition Target - Valeant Pharmaceuticals International, Inc. (NYSE:VRX)*/

– Valeant (NYSE:VRX) has many challenges going forward, but there is still fundamental value in the company’s portfolio.If Valeant’s market cap falls significantly below where it currently is, the company may make for a good acquisition target.Even now at around $5 billion in equity value and $30 billion in debt, Valeant’s enterprise value is less than 9x EBITDA while the going rate for pharmaceutical acquisitions is a 15x EBITDA multiple.
.

read more from here

read more
visit us

business

About finance market

Avatar for finance market

Check Also

Wells Fargo stock has fallen 1.32% to $52.41 picture-12448-310x165

Wells Fargo stock has fallen 1.32% to $52.41

Warren Buffett’s Berkshire Hathaway (BRKA) sold a portion of its stake in Wells Fargo yesterday. …